| Bioactivity | HDAC6-IN-29 (compound 11g), hydroxamic analogue, is a HDAC6 inhibitor. HDAC6-IN-29 has potent antiproliferative activity against CAL-51 cells (IC50 = 1.17 μM) and is able to induce apoptosis and cause accumulation of cells in the S phase of the cell cycle. HDAC6-IN-29 can be used for the research of cancer[1]. |
| Target | IC50: 1.17 μM (CAL-51 cells). |
| Name | HDAC6-IN-29 |
| Formula | C38H51ClFN5O3 |
| Molar Mass | 680.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dai L, et al. Exploring Derivatives of Quinolizidine Alkaloid Sophoridine in the Design and Biological Mechanistic Evaluation of Histone Deacetylase Inhibitors for Triple‐Negative Breast Cancer [J]. ChemMedChem, 2023: e202300467. |